Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

2.

Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?

Bergmann F, Breinig M, Höpfner M, Rieker RJ, Fischer L, Köhler C, Esposito I, Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P, Kern MA.

Am J Gastroenterol. 2009 Jan;104(1):171-81. doi: 10.1038/ajg.2008.33.

PMID:
19098866
3.

Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.

Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Riggs PK, Pavone AI, Sawicki J, Fischer SM.

Neoplasia. 2008 Aug;10(8):782-96.

4.

Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers.

Hasan S, Satake M, Dawson DW, Funahashi H, Angst E, Go VL, Reber HA, Hines OJ, Eibl G.

Pancreas. 2008 Aug;37(2):121-7. doi: 10.1097/MPA.0b013e31816618ba.

PMID:
18665070
5.

Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.

Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA, Sarkar FH.

Mol Cancer Ther. 2008 Jun;7(6):1708-19. doi: 10.1158/1535-7163.MCT-08-0354.

6.

A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.

Cai Y, Lee YF, Li G, Liu S, Bao BY, Huang J, Hsu CL, Chang C.

Int J Cancer. 2008 Jul 1;123(1):195-201. doi: 10.1002/ijc.23481.

7.

Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors.

Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT.

Gastroenterology. 2007 Dec;133(6):1869-81. Epub 2007 Sep 14.

8.

Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.

Dediu M, Median D, Alexandru A, Vremes G, Gal C.

J BUON. 2007 Sep;12 Suppl 1:S137-49. Review.

PMID:
17935272
9.

Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.

Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A.

Mol Cancer Ther. 2007 Oct;6(10):2757-65. Epub 2007 Oct 3.

10.

Glottic versus supraglottic tumors: differential molecular profile.

Kourelis K, Papadas T, Vandoros G, Goumas P, Sotiropoulou-Bonikou G.

Eur Arch Otorhinolaryngol. 2008 Jan;265(1):79-84. Epub 2007 Oct 2.

PMID:
17909831
11.

Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines.

Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, Aderka D, Ben-Yosef R.

Cancer Invest. 2007 Sep;25(6):411-8.

PMID:
17882652
12.

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23.

PMID:
17452677
13.

Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.

Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A.

Clin Cancer Res. 2007 Apr 1;13(7):2226-35.

14.

Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity.

Lev-Ari S, Starr A, Vexler A, Karaush V, Loew V, Greif J, Fenig E, Aderka D, Ben-Yosef R.

Anticancer Res. 2006 Nov-Dec;26(6B):4423-30.

15.

Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy.

Logan RM, Gibson RJ, Sonis ST, Keefe DM.

Oral Oncol. 2007 Apr;43(4):395-401. Epub 2006 Sep 18.

PMID:
16979925
16.
17.

Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas.

Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV.

Mod Pathol. 2005 Oct;18(10):1329-35.

18.

Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.

El-Rayes BF, Ali S, Sarkar FH, Philip PA.

Mol Cancer Ther. 2004 Nov;3(11):1421-6.

19.
20.

Supplemental Content

Support Center